Star Tribune, October 25, 2016. The U.S. Food and Drug Administration has set up a new webpage where the public can report allegations of regulatory misconduct against medical device makers and marketers. “This is a good idea, but the question is: what resources will the Center [for Devices and Radiological Health] devote to this to ensure that the allegations of misconduct are followed up and dealt with accordingly?” asked Diana Zuckerman, president of the National Center for Health Research.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
Obama on Obamacare: This Law ‘Has Done What It Was Designed to Do’
POLITICO, October 21, 2016. The president’s hour-long speech on Thursday — his most extensive comments on his signature health law in months — was wonky, feisty and overtly political.
Read More »Bamboozled: Action in NJ to Ban ‘A Clear and Present Danger’ to Babies
NJ.com, October 20, 2016. A host of consumer safety and public health organizations have called for stronger action on dangerous supplemental mattresses, including NCHR.
Read More »With Overactive Bladder, Drug Companies Helped Create $3 Billion Market
MedPage Today, Milwaukee Journal Sentinel, October 15, 2016. Diana Zuckerman, president of the National Center for Health Research noted there is another factor arguing against the use of drugs to treat overactive bladder. “All of these drugs have the potential for serious risk,” she said. “So what’s the actual benefit? To weigh that against risks that can be serious, it’s pretty unimpressive.”
Read More »Anthem Says Will Not Cover Sarepta’s Approved Duchenne Drug
Reuters, October 7, 2016. To keep health insurance affordable, companies need to ensure that they are paying for safe and effective treatments, said Diana Zuckerman, president of non-profit organization National Center for Health Research. “When FDA fails to ensure those standards, then ‘FDA approval’ is no longer a gold standard that insurance companies can rely on,” she said.
Read More »